Navigation Links
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Date:2/25/2008

PEC) scores at 20 minutes post- dose, as compared to placebo. The effectiveness of the 10 mg dose was sustained throughout the 24-hour study period, as compared to placebo.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. AZ-003 (Staccato fentanyl), which is partnered with Endo Pharmaceuticals in North America, for the treatment of breakthrough pain and AZ-007 (Staccato zaleplon) for the treatment of insomnia are in Phase 1 testing. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential and safety of AZ-004, the development of the Company's product candidates, projected clinical trial enrollment and data repor
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 18, 2014 American Process Inc. ... formed a partnership with researchers at Georgia Institute ... Technology, and the USDA’s Forest Products Laboratory to ... nanocellulose. Nanocellulose is a rapidly emerging high performance ... project is to replace heavy steel structures within ...
(Date:11/18/2014)... , Nov. 18, 2014  Asterias Biotherapeutics, ... in the emerging field of regenerative medicine, today ... (oligodendrocyte progenitor cells) for complete cervical spinal cord ... ten "Top Advanced Therapies Projects to Watch" by ... to receive this significant industry honor, which represents ...
(Date:11/16/2014)... The “Fluid Management & Visualization Systems Market”, ... with an analysis and forecast of value by ... warming and waste management. Along with this, the ... by applications and regions are also discussed in ... $19,285.5 million in 2013 and is expected to ...
(Date:11/15/2014)... The International Society for Cardiovascular ... society’s Governing Board has grown with the additions ... officer and Dr. Charles Simonton, divisional vice president, ... Mr. Rowe and Dr. Simonton are both medical ... , Dr. Nabil Dib, ISCTR President stated, “We ...
Breaking Biology Technology:American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference 2Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference 3Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 2Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 3Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 4International Society for Cardiovascular Translational Research Governing Board Adds Medical Industry Leaders 2
... InSightec Ltd. announced,today that the U.S. Food and Drug ... 2000 MR-guided Focused Ultrasound,(MRgFUS) system for the treatment of ... the agency allows,physicians to treat up to 100% of ... up to half the fibroid tissue. , ...
... Control of the Entire Clinical Trial Registration Process ... Adhering to Changing Regulatory Requirements; Two Top-Ten Pharmaceutical ... Registration and Results Disclosure ProcessesNEW YORK, April 7 ... ), a leading services firm that provides ...
... Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) today ... clinical trial to evaluate the objective tumour response ... in patients with advanced cancers. , A total ... (melanoma (5), colorectal (4), gastric (1), pancreas (1), ...
Cached Biology Technology:FDA Approves Label Change for Non-Invasive Fibroid Treatment 2FDA Approves Label Change for Non-Invasive Fibroid Treatment 3Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 2Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 3Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 4Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial 2Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial 3
(Date:11/11/2014)... Nov. 11, 2014  Forensicon, Inc., a ... pleased to announce the promotion of Yaniv Schiff ... Digital Forensics. In Schiff,s new role as Director, he ... of digital forensics examiners and provide leadership within the ... - http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined ...
(Date:11/7/2014)... Leading Biometric companies aim to provide ... online transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... BABA ), Google Inc. (NASDAQ: GOOG ), Microsoft ... EBAY ) and MasterCard Inc. (NYSE: MA) ... biometric authentication company focused on the growing mobile commerce is ...
(Date:11/6/2014)... - Insilico Medicine, Inc, a Baltimore-based bioinformatics company ... diseases announced a research collaboration with the international ... Inc (OTC: CSBR). , "There are many companies ... Champions Oncology,s TumorGraft technology is unique in a ... experimentally generating vast amounts of valuable data. Our ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... Approximately 55 percent of the horseradish produced in the ... the self-proclaimed "Horseradish Capital of the World." The product ... for gourmet and industrial use. But when crop sciences ... Illinois in 1999, he was told that growers had ...
... condition that causes frequent nighttime trips to the ... that shrinks the prostate, suggests a study being presented ... Meeting in New Orleans. The early findings hail from ... (PAE), which reduces blood flow to the prostate, thus ...
... Calif. , April 15, 2013  Medbox, Inc. (OTC ... industry specific consulting services and patented systems to various ... the standard bearer of corporate governance and transparency in the ... to its shareholders concerning the status of past, present, ...
Cached Biology News:Getting to the root of horseradish root problems 2Nonsurgical treatment turns back the clock, shrinks enlarged prostate 2Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 2Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 3Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 4Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 5
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Sulfadimethoxine (CH-2027)...
Bovine Pulmonary Artery Smooth Muscle Cells (BPASMC) (>500,000 cells)...
... The EC3 Darkroom is designed for ... The EC3 systems offer direct control ... and darkroom settings by hand , A ... the best system for all fluorescent and ...
Biology Products: